January 5, 2022 7:47am

Another indication: a very weak after and pre-market

Pre-open indications: 3 BUYs and 6 SELLs

What I provide is an intelligence daily. RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.


Dow futures are UP +0.03% (+10 points), S&P futures are DOWN -0.05% (-2 points) and NASDAQ futures are DOWN -0.34% (-52 points)

 

Stock futures were vacillating and flat in early morning trading Wednesday after the Dow yesterday notched a record close,

European stocks were struggling yet, trading slightly higher as global markets keep an eye on U.S. bond yields,

Asia-Pacific stocks were lower, as the region also came under pressure amid rising U.S. bond yields.

 

Economic Data Docket: investors are set to receive more data on the labor market, with ADP releasing a fresh monthly print on private payroll gains for December. This report is expected to show 410,000 private payrolls returned in December, slowing slightly from November's rise of 534,000. The report comes, as usual, two days before the Labor Department's monthly jobs report, which is also expected to show non-farm payroll gains of more than 400,000 for the final month of 2021 as the labor market recovery extended further.

 

Henry’omics:

investors are look for clues on where the cell and gene therapy sector and more when they are headed into a sustaining session, week and extremely impossible month

Rising Treasury yields have shaken the market rally to start the new year, a time that can often be volatile.

The Russell 2000 hit resistance at its 50-day line but is holding above its 200-day line. The small-cap index is a proxy for market breadth, which had been improving over the past two weeks after a long stretch of weakness. Winners narrowly topped losers on the NYSE but lagged on the Nasdaq. <IBD>

 

If you didn’t remember what happen Tuesday night and the last session of 2021’s close, you won’t be prepared for today’s session:

Tuesday’s evening’s recap: “from one extreme – a positive close to the depths of a negative close, the cell and gene therapy sector share pricing movement. What did I warn of this a.m., “Beware the upcoming algorithmic momentum road blocks” Also, the economics are OFF!”https://www.regmedinvestors.com/articles/12242

 

Companies in my headlights – It’s your decision; I provide an idea and context:

Probabilities versus aftermarket/pre-open share pricing indication moves:

Maintaining SELL:

AxoGen (AXGN) closed up +$0.46 to $10.44 after Monday’s +$0.61 or +6.51% to $9.98 with a negative -$0.04 or -0.38% pre-market indication,

Editas Medicine (EDIT) closed down -$1.23 to $26.40 after Monday’s +$1.08 or +4.07% to $27.63 after Friday’s down -$1.24 to $26.55 with a negative -$0.40 or -1.52% pre-market indication,

CRISPR Therapeutics (CRSP) closed down -$5.99 to $73.25 with a negative -0.57 or -0.78% pre-open indication.

Cellectis SA (CLLS) closed down -$0.49 or -5.59% to $8.28 with a negative -$0.18 or -2.17% pre-open indication. News this a.m., “ file:///C:/Users/hwm/Downloads/Cellectis_Corporate-Presentation_JANUARY_2021_.pdf  

 

BUY:

Alnylam Pharmaceuticals (ALNY) closed down -$8.68 or -4.99% to $165.23 with a positive +$0.27 or +0.16% pre-open indication.

Applied Genetic Technologies (AGTC) closed down -$0.10 to $1.96 after Monday’s $0.16 to $2.06 with a positive +$0.08 or +4.08% pre-open indication.

 

Maintaining SELL:

Biostage (OTCQB: BSTG) closed up +$0.02 with 1626 shares traded after Monday’s flat with 20 shares traded after Friday’s down -$0.05 with 1,001 shares traded, Thursday’s +$0.05 with 600 shares traded and last Wednesday’s -$0.01 with 500 shares traded and last Tuesday’s $0.00 with 0 shares traded. Notice how the shares traded with and without the manipulated share pricing by volume stimulation; just a “House of Cards”?

bluebird bio (BLUE) closed down -$0.32 to $10.28 after Monday’s +$0.61 or +6.11% to $10.60 with a negative -$0.13 or -1.26% pre-market indication,

 

Maintaining BUY:

Intellia Therapeutics (NTLA) closed down -$5.45 or -4.58% to $113.54 after Monday’s -$3.00 to $118.24 with a negative -$0.54 or -0.48% premarket indication,

 

The BOTTOM LINE: the “BUY” zone is questionable …

I am NOT changing my position, “Brace for more choppiness heading into the start of the year.”

I used to think negativity was a state of mind. Now, having watched for long enough, I have come to realize that negativity can be a character trait

The volatile nature of cell, gene and biotech stocks is a double-edged sword, meaning these stocks can produce gains but, sustainability or lack thereof, has been a factor through 2021 that I believe will continue into 2022.

Boom or bust as many miss end-points incurring weighty losses if a drug trial fails to perform or comes to market without any following.

Risks are also due to the possibility that many products under development may never make it to market. Share pricings were NOT maintained in 2021, begetting the collapse of many company’s pricings as months wore on.

Early January 2022 can deliver some gains but also generate algorithmic based losses.

I say today what others won't, so you can do what others can't whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors

I still have a hang-up with investment bank rankings, they don’t take the daily, monthly, or even quarterly share pricing effects into consideration. Buy-side analysts work for funds that purchase or actively trade the securities they cover and even they have their lapses.

I have “lived” on both sides and “find’ that “big spikes are common in these markets but, they are usually short in duration.”

During 2021, the sector responded only with fluctuating sessions that were driven by algorithms.

So, my bottom of the Bottom Line, Investors should be extremely cautious about adding any new exposure.

The cell and gene therapy sector has a downside bias and is a dangerous “spot”; to play in. It's an environment that lures investors in, only to sell off sharply again.

If you want to buy, focus only on stocks showing exceptional sustainability.

It's perfectly acceptable to watch from the sidelines and wait for the sector to prove itself amid the recent losses.

RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.

WHY do I keep reporting on Biostage (BSTG): When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.